Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate
US-2024374734-A1 · Nov 14, 2024 · US
US10064875B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10064875-B2 |
| Application number | US-201815928332-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 22, 2018 |
| Priority date | Aug 31, 2009 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Opening claim text (preview).
What is claimed is: 1. A topical pharmaceutical composition comprising: clobetasol; an emulsifying agent; water; a water-immiscible substance; and a skin penetration enhancer selected from the group consisting of butanediol, polyethylene glycol monolaurate, diethylene glycol monoethyl ether, dimethylsulfoxide, decylmethylsulfoxide, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, methyl propionate, ethyl oleate, and combinations thereof; wherein the composition is non-foaming, propylene glycol-free, alcohol-free, and propellant-free. 2. The composition according to claim 1 , wherein the clobetasol is clobetasol propionate. 3. The composition according to claim 1 , wherein the emulsifying agent comprises a cationic surfactant, anionic surfactant, zwitterionic surfactant, amphoteric surfactant, or any combination thereof. 4. The composition according to claim 3 , wherein an emulsifying agent comprises a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydrides with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, or any combination thereof. 5. The composition according to claim 1 , wherein the water-immiscible substance comprises vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof. 6. The composition according to claim 1 , wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight. 7. The composition according to claim 6 , wherein the skin penetration enhancer comprises a polyol or ester thereof, an ether, a sulfoxide, a fatty acid, a fatty acid ester, or any combinations thereof. 8. The composition of claim 1 further comprising an emollient comprising an oil of natural origin, a fatty acid or a monohydric alcohol ester thereof, a glycol, a branched aliphatic alcohol, or any combination thereof. 9. A method of treating a skin condition in a subject comprising topically administering an effective amount of a composition according to claim 1 to the subject; wherein the skin condition is one or more of atopic dermatitis, seborrheic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction. 10. A propellant-free topical composition, comprising: clobetasol; an emulsifying agent from about 0.25% w/w to about 45% w/w of the composition; a skin penetration enhancer from about 0.001% w/w to about 15% w/w of the composition; and a water-immiscible substance; wherein the composition is non-foaming, propylene glycol-free and alcohol-free. 11. The composition according to claim 10 , wherein the clobetasol is clobetasol propionate. 12. The composition according to claim 10 , wherein the emulsifying agent comprises a cationic surfactant, anionic surfactant, zwitterionic surfactant, amphoteric surfactant, or any combination thereof. 13. The composition according to claim 12 , wherein an emulsifying agent comprises a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydrides with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, or any combination thereof. 14. The composition according to claim 10 , wherein the water-immiscible substance comprises vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof. 15. The composition according to claim 10 , wherein the skin penetration enhancer comprises a polyol or ester thereof, an ether, a sulfoxide, a fatty acid, a fatty acid ester, or any combinations thereof. 16. The composition of claim 10 further comprising an emollient comprising an oil of natural origin, a fatty acid or a monohydric alcohol ester thereof, a glycol, a branched aliphatic alcohol, or any combination thereof. 17. A method of treating a skin condition in a subject comprising topically administering an effective amount of a composition according to claim 10 to the subject; wherein the skin condition is one or more of atopic dermatitis, seborrheic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction.
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
designed to control volume of flow, e.g. with adjustable passages {(B05B11/0094 takes precedence)} · CPC title
Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) · CPC title
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.